![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
June 21, 2022
Reflections on the spring conference season, including highlights from the Spring Group Meeting and ASCO's Annual Meeting
June 21, 2022
This single-arm phase 2 study aims to rid patients of residual disease following initial treatment
June 21, 2022
The Group is recognizing Dr. Eads as an exceptional medical oncologist and committed educator who is making significant research contributions as an international disease expert in neuroendocrine tumors and gastroesophageal malignancies
June 21, 2022
ECOG-ACRIN researchers presented a wide range of study results at the 2022 ASCO Annual Meeting
June 21, 2022
This study seeks to determine if neoadjuvant treatment with durvalumab and chemotherapy improves patient outcomes over chemotherapy alone
June 21, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more